Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

RITE AID, FTC NEGOTIATIONS HALT OVER STORES IN OHIO, WEST VIRGINIA AND SOUTH CAROLINA; RITE AID ALLEGES FTC BIAS AGAINST RITE AID/REVCO MERGER

Executive Summary

The termination of negotiations between Rite Aid and the Federal Trade Commission over Rite Aid's proposed merger with Revco resulted from FTC's demand that substantially all Revco stores in Ohio, West Virginia and South Carolina be divested, Rite Aid CEO Martin Grass told a teleconference April 24. By halting negotiations with FTC and calling off the merger before the April 29 closing date, Rite Aid avoided penalty costs for failing to meet the merger contract.

You may also be interested in...



FTC Considering Litigation In Lieu Of Divestiture For Drug Chain Mergers

The Federal Trade Commission is contemplating using antitrust litigation instead of its traditional strategy of requiring pharmacy chains to divest store locations in a merger, FTC Bureau of Competition Assistant Director of the Office of Policy & Evaluation David Balto told the National Association of Chain Drug Stores.

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

UsernamePublicRestriction

Register

ID001014

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel